

Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/VC4374F11695EN.html>

Date: February 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: VC4374F11695EN

Abstracts

Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology),

Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Playe...

complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 10, 2, 4 and 1 respectively.

Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural Ulcer) (Dermatology).

The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Venous Leg Ulcers (Crural Ulcer) - Overview

Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development

Aurealis Therapeutics AG

CytoTools AG

Energenesis Biomedical Co Ltd

GangaGen Biotechnologies Pvt Ltd

Hypo-Stream Ltd

Mallinckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma AB

QBiotics Group Ltd

Reponex Pharmaceuticals AS

RHEACELL GmbH & Co KG

Tissue Repair Pty Ltd

Venturis Therapeutics Inc

Zhitty Genesis Medicine Inc

Venous Leg Ulcers (Crural Ulcer) - Drug Profiles

Amesandar - Drug Profile

Product Description

Mechanism Of Action

History of Events

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVBT-141 - Drug Profile

Product Description

Mechanism Of Action

CVBT-141B - Drug Profile

Product Description

Mechanism Of Action

diperoxochloric acid - Drug Profile

Product Description

Mechanism Of Action

History of Events

EBC-1013 - Drug Profile

Product Description

Mechanism Of Action

ENERGIF-703 - Drug Profile

Product Description

Mechanism Of Action

EscharEx - Drug Profile

Product Description

Mechanism Of Action

History of Events

EscharEx Second Generation - Drug Profile

Product Description

Mechanism Of Action

History of Events

FGF-1 - Drug Profile

Product Description

Mechanism Of Action

molgramostim - Drug Profile

Product Description

Mechanism Of Action

History of Events

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

P-128 - Drug Profile

Product Description

Mechanism Of Action

ropocamptide - Drug Profile

Product Description

Mechanism Of Action

History of Events

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Venous Leg Ulcers - Drug Profile

Product Description

Mechanism Of Action

History of Events

TR-987 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Venous Leg Ulcers (Crural Ulcer) - Dormant Projects

Venous Leg Ulcers (Crural Ulcer) - Discontinued Products

Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones

Featured News & Press Releases

Jan 24, 2022: MediWound announces positive topline results from its U.S. phase 2 trial of EscharEx for debridement of chronic wounds

Oct 25, 2021: Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers

Oct 19, 2021: From chronic to curable RHEACELL is developing a novel cell-therapy agent for the treatment of chronic venous ulcers

Jul 28, 2021: MediWound announces positive outcome of interim assessment for its EscharEx U.S. phase 2 adaptive design study

Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal

Jun 09, 2021: MediWound completes patient enrollment for interim assessment of its U.S. EscharEx phase 2 adaptive design study

Apr 22, 2021: MediWound enrolls first patient in phase 2 pharmacology study of EscharEx

Jan 11, 2021: MediWound provides progress update on its EscharEx clinical development program

Nov 20, 2020: Clarification of outcome in the clinical trial HEAL LL-37

Nov 19, 2020: Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers

Oct 08, 2020: The IND application of ENERGI-F703 for treating venous leg ulcers (VLU) has been approved by TFDA

Jul 14, 2020: Promore Pharma is granted a patent for ropocamptide in the US

Mar 24, 2020: Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial

Dec 10, 2019: Promore Pharma has finalized recruitment of patients in HEAL LL-37 early

Dec 03, 2019: MediWound Initiates U.S. Phase 2 Adaptive design study of EscharEx for treatment of Venous Leg Ulcers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Aurealis Therapeutics AG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Energenesis Biomedical Co Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Hypo-Stream Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Mallinckrodt Plc, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by QBiotics Group Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Reponex Pharmaceuticals AS, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by RHEACELL GmbH & Co KG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Tissue Repair Pty Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Venturis Therapeutics Inc, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Zhitty Genesis Medicine Inc, 2022
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2022
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2022 (Contd..1)
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/VC4374F11695EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VC4374F11695EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

